Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen’s mission of improving the diagnosis and treatment of autoimmune diseases.
Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune research. At the same time, Dr. Mahler initiated a productive and lasting collaboration with one of his mentors, Dr. Marvin J. Fritzler, a thought leader in the field whose research spans a wide range of topics, including autoimmune disease, the biology of autoantigens, and novel diagnostic technologies.
Over the course of his distinguished career, Dr. Mahler has held key positions at various diagnostic companies, most recently serving as Senior Vice President of Research Development and Business Development at Werfen. His transformative work has led to the discovery of several novel autoantigens and the development of innovative diagnostic solutions. His scientific contributions have resulted in over 300 peer-reviewed publications and numerous patents, advancing the accurate diagnosis of autoimmune diseases.
“We are thrilled to welcome Dr. Mahler to Exagen,” said John Aballi, President and CEO at Exagen. “His deep understanding of autoimmune research and commitment to scientific innovation will play a pivotal role in strengthening our diagnostic capabilities and advancing patient care.”
In his new role at Exagen, Dr. Mahler will spearhead strategic initiatives aimed at enhancing precision diagnostics for autoimmune diseases. His expertise will support Exagen’s development of cutting-edge tools to improve patient outcomes.
“I am very excited to join the talented Exagen team as they work to revolutionize the management of autoimmune diseases,” said Dr. Mahler. “The company is at an exciting stage with several innovative projects already in motion. I’m especially energized by the opportunity to combine my 20+ years of experience with the patient-centric approach developed by Exagen’s leadership team.”
About Exagen
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
The Editorial Team at Healthcare Business Today is made up of experienced healthcare writers and editors, led by managing editor Daniel Casciato, who has over 25 years of experience in healthcare journalism. Since 1998, our team has delivered trusted, high-quality health and wellness content across numerous platforms.
Disclaimer: The content on this site is for general informational purposes only and is not intended as medical, legal, or financial advice. No content published here should be construed as a substitute for professional advice, diagnosis, or treatment. Always consult with a qualified healthcare or legal professional regarding your specific needs.
See our full disclaimer for more details.
